DE60038894D1 - Screeningverfahren für geeignete wirkstoffe - Google Patents

Screeningverfahren für geeignete wirkstoffe

Info

Publication number
DE60038894D1
DE60038894D1 DE60038894T DE60038894T DE60038894D1 DE 60038894 D1 DE60038894 D1 DE 60038894D1 DE 60038894 T DE60038894 T DE 60038894T DE 60038894 T DE60038894 T DE 60038894T DE 60038894 D1 DE60038894 D1 DE 60038894D1
Authority
DE
Germany
Prior art keywords
active substances
screening process
suitable active
treating
related diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60038894T
Other languages
English (en)
Inventor
Herwig Brunner
Juergen Bernhagen
Robert Kleemann
Ralf Mischke
Afroditi Kapurniotu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fraunhofer Gesellschaft zur Forderung der Angewandten Forschung eV
Original Assignee
Fraunhofer Gesellschaft zur Forderung der Angewandten Forschung eV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7930501&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60038894(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fraunhofer Gesellschaft zur Forderung der Angewandten Forschung eV filed Critical Fraunhofer Gesellschaft zur Forderung der Angewandten Forschung eV
Application granted granted Critical
Publication of DE60038894D1 publication Critical patent/DE60038894D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
DE60038894T 1999-11-26 2000-11-02 Screeningverfahren für geeignete wirkstoffe Expired - Lifetime DE60038894D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19957065A DE19957065B4 (de) 1999-11-26 1999-11-26 Screening-Verfahren für Arzneistoffe
PCT/EP2000/010814 WO2001038566A2 (en) 1999-11-26 2000-11-02 Screening method for candidate drugs

Publications (1)

Publication Number Publication Date
DE60038894D1 true DE60038894D1 (de) 2008-06-26

Family

ID=7930501

Family Applications (2)

Application Number Title Priority Date Filing Date
DE19957065A Expired - Fee Related DE19957065B4 (de) 1999-11-26 1999-11-26 Screening-Verfahren für Arzneistoffe
DE60038894T Expired - Lifetime DE60038894D1 (de) 1999-11-26 2000-11-02 Screeningverfahren für geeignete wirkstoffe

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE19957065A Expired - Fee Related DE19957065B4 (de) 1999-11-26 1999-11-26 Screening-Verfahren für Arzneistoffe

Country Status (9)

Country Link
US (2) USRE43497E1 (de)
EP (3) EP2033972A1 (de)
JP (1) JP2004500807A (de)
AT (1) ATE395433T1 (de)
AU (1) AU1855401A (de)
CA (1) CA2391392C (de)
DE (2) DE19957065B4 (de)
ES (1) ES2306672T3 (de)
WO (1) WO2001038566A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10054303B4 (de) * 2000-11-02 2007-11-08 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Analoga, Agonisten, Antagonisten und Varianten der Oxidoreduktase-Enzymaktivität des Makrophagen-Migrations-Inhibitions-Faktors (MIF) als Immunmodulatoren, Therapeutika, Diagnostika und Screening-Agenzien bei inflammatorischen und Immunerkrankungen
AU2003235122A1 (en) * 2002-04-26 2003-11-10 Takeda Chemical Industries, Ltd. Cell death inhibitor
JP4510490B2 (ja) * 2004-03-16 2010-07-21 国立大学法人 奈良先端科学技術大学院大学 Ｊａｂ１／ＣＯＰ９シグナロソームを利用した細胞増殖等の制御方法
GB0425972D0 (en) * 2004-11-25 2004-12-29 Celltech R&D Ltd Biological products
CN100457895C (zh) * 2006-05-24 2009-02-04 中国科学院生物物理研究所 鼠抗人巨噬细胞迁移抑制因子单克隆抗体及其应用
EP2074138A4 (de) * 2006-09-19 2009-12-30 Phylogica Ltd Neuroprotektive peptidinhibitoren der ap-1-signalvermittlung und anwendungen davon
EP2066812A4 (de) * 2006-09-21 2010-04-28 Univ Rochester Zusammensetzungen und verfahren in zusammenhang mit proteinverschiebungstherapie für myotone dystrophie
WO2008154700A1 (en) * 2007-06-20 2008-12-24 Phylogica Limited Compositions and uses thereof for the treatment of acute respiratory distress syndrome (ards) and clinical disorders associated with therewith
CA2716628A1 (en) * 2008-03-24 2009-10-01 Carolus Therapeutics, Inc. Methods and compositions for treating atherosclerosis and related conditions
WO2012103442A2 (en) 2011-01-28 2012-08-02 The Broad Institute, Inc. Paired end bead amplification and high throughput sequencing
WO2013010955A1 (en) 2011-07-15 2013-01-24 Morphosys Ag Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt)
WO2013022961A1 (en) 2011-08-08 2013-02-14 3The Broad Institute Compositions and methods for co-amplifying subsequences of a nucleic acid fragment sequence
CN109212228A (zh) * 2018-09-10 2019-01-15 南京昂科利医药科技创新研究院有限公司 Mif作为早期帕金森病诊断的生物标志物在制备帕金森病诊断试剂中的用途
CN109666699B (zh) * 2018-12-29 2023-02-28 杭州科兴生物科技有限公司 一种基于lag-3/mhc ii阻断功能及其生物效应的药物快速筛选方法
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2403098A1 (fr) 1977-09-19 1979-04-13 Merieux Inst Nouveau materiau capable de fixer de facon reversible des macromolecules biologiques, sa preparation et son application
US4491632A (en) 1979-10-22 1985-01-01 The Massachusetts General Hospital Process for producing antibodies to hepatitis virus and cell lines therefor
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
DE3167442D1 (en) 1980-07-07 1985-01-10 Nat Res Dev Improvements in or relating to cell lines
US4341761A (en) 1980-07-25 1982-07-27 E. I. Du Pont De Nemours And Company Antibodies to immunogenic peptides and their use to purify human fibroblast interferon
US4466917A (en) 1981-02-12 1984-08-21 New York University Malaria vaccine
US4493890A (en) 1981-03-23 1985-01-15 Miles Laboratories, Inc. Activated apoglucose oxidase and its use in specific binding assays
JPS5873993U (ja) 1981-11-12 1983-05-19 三菱電機株式会社 ２気筒回転式圧縮機
US4399121A (en) 1981-11-04 1983-08-16 Miles Laboratories, Inc. Iodothyronine immunogens and antibodies
US4427783A (en) 1981-12-14 1984-01-24 Hoffmann-La Roche Inc. Immunoassay of thymosin α1
DE69033982T2 (de) * 1989-03-21 2002-10-24 The United States Of America, Represented By The Secretary Matrizenmetalloproteinase-inhibitor-peptide
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
DE69329112T2 (de) * 1992-05-06 2000-12-14 Immunomedics, Inc. Intraoperative, intravaskulare und endoskopische bestimmung und behandlung von verletzungen und tumoren
US6774227B1 (en) * 1993-05-17 2004-08-10 Cytokine Pharmasciences, Inc. Therapeutic uses of factors which inhibit or neutralize MIF activity
US5599677A (en) * 1993-12-29 1997-02-04 Abbott Laboratories Immunoassays for prostate specific antigen
NZ306767A (en) * 1995-04-11 2000-03-27 Univ Johns Hopkins Method of identifying molecular interactions employing counterselection and at least two hybrid molecules or two hybrid systems
US5910427A (en) * 1995-06-22 1999-06-08 La Jolla Institute For Allergy And Immunology Antigen non-specific glycosylation inhibiting factor derivatives
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
US6068838A (en) 1996-04-29 2000-05-30 Baxter Aktiengesellschaft Purified multimerase
EP1034274A2 (de) * 1997-11-07 2000-09-13 E.I. Du Pont De Nemours And Company Pflanze homolog zur hefe-pad1, hefe-cmr1, und menschlicher jab1, die regulatoren von ap-1 type transkriptionsfaktoraktivität
CA2318811A1 (en) * 1998-01-30 1999-08-26 Cold Spring Harbor Laboratory Modulation of cell proliferation, methods and reagents
WO2001064749A2 (en) * 2000-02-28 2001-09-07 Idec Pharmaceuticals Corporation Method for preparing anti-mif antibodies
DE10054303B4 (de) * 2000-11-02 2007-11-08 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Analoga, Agonisten, Antagonisten und Varianten der Oxidoreduktase-Enzymaktivität des Makrophagen-Migrations-Inhibitions-Faktors (MIF) als Immunmodulatoren, Therapeutika, Diagnostika und Screening-Agenzien bei inflammatorischen und Immunerkrankungen

Also Published As

Publication number Publication date
DE19957065B4 (de) 2005-01-05
EP1235934B1 (de) 2008-05-14
WO2001038566A3 (en) 2001-11-29
AU1855401A (en) 2001-06-04
EP2033972A1 (de) 2009-03-11
CA2391392A1 (en) 2001-05-31
USRE43497E1 (en) 2012-06-26
DE19957065A1 (de) 2001-06-28
JP2004500807A (ja) 2004-01-15
WO2001038566A2 (en) 2001-05-31
EP1990413A1 (de) 2008-11-12
US7303885B1 (en) 2007-12-04
CA2391392C (en) 2012-07-17
EP1235934A2 (de) 2002-09-04
ATE395433T1 (de) 2008-05-15
EP1990413B1 (de) 2013-07-24
ES2306672T3 (es) 2008-11-16

Similar Documents

Publication Publication Date Title
DE60038894D1 (de) Screeningverfahren für geeignete wirkstoffe
DE59608103D1 (de) Sortiervorrichtung für biologische Zellen oder Viren
DE69631120D1 (de) Vorrichtung zum bestrahlen von lebenden zellen
DE69534405D1 (de) Vorrichtung zum gewinnen von autologen, mikrovaskulären endothelialen zellen enthaltendem fettgewebe
DE69829089D1 (de) Vorrichtung und Apparat zur gleichzeitigen Detektion von mehreren Analyten
DE69626832D1 (de) Blutbehandlungssysteme und methoden zur gewinnung von mononuklearen zellen
ATE346291T1 (de) Mehrschichtige feuchtigkeitsbarriere für eine vorrichtung zum prüfen von elektrochemischen zellen
ATE263377T1 (de) Vorrichtung für klinische analysen
DE69711655D1 (de) Optischer sensor zum nachweis von in wasser gelösten oder dispergierten chemischen substanzen
ATE110415T1 (de) Verbessertes verfahren und apparat, um biologische substanzen in lebenden zellen einzuführen.
DE69528153D1 (de) Prüfung von nachgemachten objekten, zum beispiel von nachgemachten geldscheinen
DK0773811T3 (da) Systemer og fremgangsmåder til at forudsige blodbehandlingsparametre
ATE408422T1 (de) Methode zur hemmung immunstimulatorischer mit dna assoziierter antworten
NO994490D0 (no) Seismisk deteksjonsapparat, samt tilknyttet fremgangsmÕte
IT1240410B (it) Apparecchio e metodo per asciugare le unghie.
DE69930404D1 (de) Methode zum nachweis von analyten
DE69618386D1 (de) Damaszener-Doppelprozess mit Löchern mit abgeschrägten Flauben
DE3778263D1 (de) Produkt und vorrichtung zum entfeuchten.
DE69021564D1 (de) Enzyme und deren verwendung zum nachweis von drogen.
DE69904531D1 (de) Gerät zum Bearbeiten von Löchern
DE3881995D1 (de) Vorrichtung und methode zum testen.
DE68909997D1 (de) Vorrichtung zur Kultur von tierischen Zellen, Kulturmethode und Mittel zum Nachweis der Kultur.
DE69529297D1 (de) Bestrahlungs- und/oder zählkammer für die neutronendetektionsanalyse
DE3862433D1 (de) Vorrichtung zum sieben von faserbrei.
NO983360D0 (no) FremgangsmÕte for overvÕkning av biologisk aktivitet i fluider

Legal Events

Date Code Title Description
8363 Opposition against the patent